Reporting Local Trials to WP8/ELN RLTWP8 Project Moshe Mittelman Tel Aviv Sourasky Medical Center Sackler School of Medicine – TA University For: WP8 /

Slides:

Advertisements

Similar presentations

In the name of GOD In the name of GOD.

Advertisements

Evidence Based Advertising “Don’t accept your dog’s admiration as conclusive evidence that you are wonderful” -Ann Landers.

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Richardson PG et al. Proc ASH 2013;Abstract 535.

Clinical and Surrogate Endpoints for Evaluating Efficacy of Alpha 1 - Proteinase Inhibitor (Human) Augmentation Therapy Topic II - Introduction Blood Products.

Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.

1 Points to Consider of Protocol on Multinational Trial Masaaki Kuwahara, Ph.D. Takeda Chemical Industries, Ltd. The 4th Kitasato-Harvard symposium,

Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.

Clinical Trials Scientific Aspects AND Legal & Procedural Aspects M K Unnikrishnan [Aug 2006]

Phase II Trials in Oncology S. Gail Eckhardt, MD Lillian Siu, MD Brian I. Rini, M.D.

Future Research Directions Improving the Chain of Recovery for Acute Stroke in Your Community.

1 FDA Trial Design Requirements for CABP David M. Shlaes MD, PhD Anti-infectives Consulting, LLC Stonington, CT.

Luveris ® New Drug Application ( ) Kate Meaker, M.S. Statistical Reviewer Division of Biometrics II Kate Meaker, M.S. Statistical Reviewer Division.

Non-Surgical Periodontal Therapy Reduces Coronary Heart Disease Risk Markers: A Randomized Controlled Trial Bokhari SAH, Khan AA, Butt AK, Azhar M, Hanif.

Yesterday, today, and tomorrow

Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.

Respiratory Effectiveness Group Study Proposal (REG) Insert name of Lead Investigator & key collaborating groups Please direct all questions and correspondence.

PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.

Evidence-Based Journal Article Presentation [Insert your name here] [Insert your designation here] [Insert your institutional affiliation here] Department.

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.

A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.

Title Line Subtitle Line Date / Student Example photos.

Successful Concepts Study Rationale Literature Review Study Design Rationale for Intervention Eligibility Criteria Endpoint Measurement Tools.

Evidence-Based Medicine Presentation [Insert your name here] [Insert your designation here] [Insert your institutional affiliation here] Department of.

Title of the Paper Your Name Critical Care Medicine School of Medicine University of Pittsburgh.

1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.

DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® STARFlex™ Septal Occlusion System with Qwik Load NMT Medical P000049/S3.

NDA SE-011 Docetaxel FDA Review. FDA Review Team Biostatistics –Clara Chu, PhD. –Gang Chen, PhD. Biopharmaceutics –Safaa Ibrahim PhD –Atiq Rahman,

AprepitantAprepitant Division of Gastrointestinal and Coagulation Drug Products Division of Gastrointestinal and Coagulation Drug Products Center for Drug.

1 Presented by Kenneth M. Verburg, Ph.D. at the Arthritis Advisory Committee meeting 07/29/02.

Understanding Clinical Trials – Part 2 Georgianne Arnold, MD Professor of Pediatrics University of Pittsburgh Medical Center Pittsburgh Children’s Hospital.

C-1 Efficacy of the Combination: Meta-Analyses Donald A. Berry, Ph.D. Frank T. McGraw Memorial Chair of Cancer Research University of Texas M.D. Anderson.

AIM Statements Tara Villareal and Leslie Cernosek M. D. Anderson Information Line.

Thrice-Weekly Glatiramer Acetate for Relapsing Forms of Multiple Sclerosis: Findings from the GALA Study Fred D. Lublin, MD Saunders Family Professor of.

Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.

European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.

1 EXPERIENCES IN EARLY PHASE STUDIES AIMED TO SELECT APPROPRIATE DOSE REGIMENS THAT LED TO SUCCESS VS. FAILURE Naitee Ting, Pfizer Global R&D.

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.

Levels of Evidence Dr Chetan Khatri Steering Committee, STARSurg.

Topic II: Heterogeneity of Commercial Alpha-1- Proteinase Inhibitor (Human) [A 1 PI ] Products – Implications for Longer-Term Safety and Efficacy? Introduction.

Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

ANCO 2006 ASH UPDATE MDS Joseph M. Tuscano, M.D. UC Davis Cancer Center.

CLINICAL EFFICACY STUDY OF BACLOFEN IN REDUCING ALCOHOL CONSUMPTION IN HIGH RISK DRINKERS Study title: Alcohol Treatment : A Pragmatic Randomized, Double-blind.

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

Secondary Analysis of Clinical Trials Data – A Biostatistician’s Experience Gui-shuang Ying, PhD Center for Preventive Ophthalmology and Biostatistics.

UOG Journal Club: February 2016

Clinical Trial Design for Second Generation TAVI - Academic View

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Sekeres MA et al. Proc ASH 2015;Abstract 908.

O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.

EMPHASIS-HF Extended Follow-up

How the Latest Data in MDD Can Guide Treatment Decisions:

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

The Safety and Efficacy of Full vs

Pilot Studies: What we need to know

What Has Been Tried and What Is True?

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Extraordinary Cases of VTE Prevention in Patients With Cancer

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

A Time for Change for Managing Patients With VTE Who Have Cancer

Managing Anemia in Lower-Risk MDS

Elevated Admission Plasma Glucose Following ACS

Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682 / Grazoprevir / MK-8408 (Ruzasvir) in Cirrhotic or Non-cirrhotic Patients with Chronic.

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Presentation transcript:

Reporting Local Trials to WP8/ELN RLTWP8 Project Moshe Mittelman Tel Aviv Sourasky Medical Center Sackler School of Medicine – TA University For: WP8 / ELN Mannheim, Feb 1, 2011

RLTWP8: Background / Problem Most clinical trials are company-driven Very few IIT, usually small scale Difficult to draw conclusions: Heterogeneity of trials Small number of patients Methods of reporting so far - failed

RLTWP8: Aim A simple method / system of communication between the centers Exchange of relevant information regarding designed / planned / ongoing clinical trials This would stimulate using similar parameters (method, dose, regimen…) Would allow data combination from trials May lead to conclusions as if it had been a larger clinical trial (not meta analysis)

RLTWP8: The Proposed Method A standard simple report form (see below) An international committee (of WP8) Chair: A leading person from a large group The committee will receive information on each local / national clinical trial The committee will review the protocol Suggestions will be made A voluntary process

A Proposed Report Form (draft) (I) Trial name / title PI / contact person Aim of the study Primary endpoint (s) Secondary endpoint (s) Regimens / medications Dose (s) Duration of the trial

A Proposed Report Form (draft) (II) Other features related to the medications Study type Number of patients to be recruited Study duration Expected results Any other relevant trial’s features

RLTWP8: Expected Results A unification or close to standardization of most national/local clinical trials The possibility of comparing, unification and possible combination of data from various trials A possible more meaningful clinically relevant conclusions

RLTWP8: Example (?) ViLen-01: A phase 2, single-arm study to determine the safety and efficacy of azacitidine and lenalidomide in higher risk MDS – A national Israeli trial A similar GFM trial ? Can we try to co-operate ?

From The Tel Aviv Sourasky Medical Center